GenomeWeb

Akonni

Jun 28, 2019

Akonni Biosystems Developing Multi-Target Infectious Diseases Tests for Newly Cleared TruDx System

Premium

The Frederick, Maryland-based firm has received regulatory clearance for a multiplexed array-based assay after more than 15 years in development.

Jun 06, 2019

Akonni Bio Obtains FDA 510(k) Clearance for TruDiagnosis MDx System, PGx Test

Akonni has received clearance for a molecular diagnostic instrument and a saliva-based pharmacogenomics test for warfarin metabolism.

Feb 05, 2019

Akonni Wins $3M NIH Contract to Develop TB Sample Prep Device

The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.

Jan 04, 2019

Akonni Biosystems Submits Multiplex Diagnostics System to FDA

Upon clearance of the platform, the company will commercialize the TruDiagnosis, an IVD system for genotyping multiple genes in a DNA sample, this year.

Aug 21, 2018

Akonni Biosystems Scores $3M NIH Grant for POC Dx Platform, Drug-Resistant TB Assay

The firm plans to make the molecular testing system accessible to low-income countries, in part by reducing costs using reel-to-reel manufacturing.

Mar 20, 2018

Akonni Biosystems Forms Chinese Commercialization Partnership with Righton

The exclusive two-way licensing deal also allows Akonni to commercialize Righton's molecular diagnostic tests outside of China.

Nov 14, 2017

Akonni Wins $300K NIH Grant for Drug-Resistant Tuberculosis Test

The grant was awarded under a program designed to help small businesses transition NIH-funded projects into the commercialization stage.

Aug 09, 2017

Akonni Biosystems Wins NIH SBIR Grant for Pediatric Respiratory Disease Diagnostics

The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.

May 15, 2017

Akonni Biosystems Raises $4M

The funding will be used in part to prepare an FDA submission for a clinical IVD pharmacogenomic test for its TruDx 2000 microarray platform.

Jan 09, 2015

Study Suggests Feasibility of Immune-Response Biomarker Panels to Detect Latent Tuberculosis

Premium

An RT-qPCR-based assay of antigen-stimulated blood is a possible next-gen approach for latent TB detection, a Cepheid executive noted in an accompanying commentary.

Breaking News

The Scan

Preprints During Lockdown

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

ApoE and COVID-19

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Search for Genetic Clues to COVID-19 Severity

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

PNAS Papers on Retinal Development, Adoptive T Cell Transfer, Blood Cell Differentiation

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

Menu